DK154430B - METHOD OF ANALOGUE FOR THE PREPARATION OF INDOLO (2,3-A) QUINOLIZIDIN OR ACID ADDITION SALTS - Google Patents

METHOD OF ANALOGUE FOR THE PREPARATION OF INDOLO (2,3-A) QUINOLIZIDIN OR ACID ADDITION SALTS Download PDF

Info

Publication number
DK154430B
DK154430B DK524978AA DK524978A DK154430B DK 154430 B DK154430 B DK 154430B DK 524978A A DK524978A A DK 524978AA DK 524978 A DK524978 A DK 524978A DK 154430 B DK154430 B DK 154430B
Authority
DK
Denmark
Prior art keywords
compound
indole
indolo
product
formula
Prior art date
Application number
DK524978AA
Other languages
Danish (da)
Other versions
DK154430C (en
DK524978A (en
Inventor
Andre Buzas
Original Assignee
Scras
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Scras filed Critical Scras
Publication of DK524978A publication Critical patent/DK524978A/en
Publication of DK154430B publication Critical patent/DK154430B/en
Application granted granted Critical
Publication of DK154430C publication Critical patent/DK154430C/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/12Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains three hetero rings
    • C07D471/14Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/10Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14Radicals substituted by nitrogen atoms, not forming part of a nitro radical

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Indole Compounds (AREA)

Description

iin

DK 154430 BDK 154430 B

Den foreliggende opfindelse angår en analogifremgangsmåde til fremstilling af hidtil ukendte indolo(2,3-a)quino-lizidiner eller farmaceutisk acceptable syreadditionssalte heraf, og fremgangsmåden ifølge opfindelsen er ejendommelig ved det i kravets kendetegnende del anførte.The present invention relates to an analogous process for the preparation of novel indolo (2,3-a) quinolizidines or pharmaceutically acceptable acid addition salts thereof, and the process according to the invention is characterized by the characterizing part of the claim.

Indolo(2,3-a)quinolizidinerne fremstillet ifølge opfindelsen har de almene formler (I) og (II): rnrn CnThe indolo (2,3-a) quinolizidines of the invention have the general formulas (I) and (II): no Cn

It J n tt'' (I) <”> hvori R betegner -COOC2H5, -COOH, -CN, en aminomethylgruppe eller en substitueret aminomethylgruppe med formlen R'-NH-CI^-, hvor R' betegner alkyl, akanoyl eller alkoxy-carbonyl med op til 5 C-atomer, phenyloxycarbonyl, di-ethylaminoethylaminocarbonyl, trimethoxybenzoyl eller guanidinocarbonyl, eller hvori R sammen med indolringens nitrogenatom betegner^N-CO-NH-CE^- eller^N-CO-. Disse sidstnævnte derivater er D homo azaeburnamoniner eller D eburnamoniner.Wherein R represents -COOC 2 H 5, -COOH, -CN, an aminomethyl group or a substituted aminomethyl group of the formula R'-NH-Cl 2 - wherein R 'represents alkyl, acanoyl or alkoxy -carbonyl having up to 5 C atoms, phenyloxycarbonyl, diethylaminoethylaminocarbonyl, trimethoxybenzoyl or guanidinocarbonyl, or wherein R together with the nitrogen atom of the indole ring represents ^ N-CO-NH-CE ^ - or ^ N-CO-. These latter derivatives are D homo azaeburnamonines or D eburnamonines.

Foretrukne forbindelser fremstillet ifølge opfindelsen er sådanne, hvor R betegner COOH, methylenaminocarbethoxy, methylenamino(3,4,5-trimethoxy)-benzoyl, methylenami-nophenoxycarbonyl, methylenureidodiethylaminoethyl, methylenaminopentanoyl, eller methylenaminopentyl.Preferred compounds of the invention are those wherein R represents COOH, methyleneamocarbethoxy, methyleneamino (3,4,5-trimethoxy) benzoyl, methyleneaminophenoxycarbonyl, methylenureidodiethylaminoethyl, methylenaminopentanoyl, or methylenaminopentyl.

DK 154430 BDK 154430 B

22

Forbindelserne fremstillet ifølge opfindelsen er bemærkelsesværdige på grund af deres indvirkning på hjernens blodcirkulation. Forbindelserne kan således formuleres som terapeutiske midler, der indeholder en eller flere af de omhandlede forbindelser i kombination med et terapeutisk acceptabelt fortyndingsmiddel eller bærestof.The compounds of the invention are remarkable because of their effect on the blood circulation of the brain. Thus, the compounds may be formulated as therapeutic agents containing one or more of the subject compounds in combination with a therapeutically acceptable diluent or carrier.

Fra FR patentskrifterne nr. 2 285 877 og nr. 2 292 475 kendes forbindelser, der er nært beslægtede med de ifølge opfindelsen fremstillede forbindelser. De således kendte forbindelser har imidlertid en væsentligt mindre effektiv indvirkning på blodcirkulationen end de omhandlede forbindelser med formel I og II, hvilket vil blive uddybet i det følgende.FR-A-2,285,877 and 2,292,475 disclose compounds which are closely related to the compounds of the invention. However, the compounds thus known have a significantly less effective effect on blood circulation than the present compounds of formulas I and II, which will be elaborated below.

Fremgangsmåden ifølge opfindelsen består i at kondensere 2-aminoethyl-3-indol med l-chlor-4-(A)-4-chlorcarbonyl-hexan, hvor A betegner -COCX^H,. eller -CN, til dannelse af det tilsvarende amid. Derefter udsættes amidet for stærk basisk påvirkning, hvorved HC1 uddrives, samtidig med at der sker en ringslutning ved nitrogenatomet på 3-indol-substituenten. Ved at behandle det således opnåede produkt med dehydratiserende middel og derefter med et perchloiratsalt opnås en quinolizidin-ringdannelse, og det resulterende quinolizidiniumperchlorat hydrogeneres til dannelse af en blanding af isomere af det korresponderende indolo(2,3-a)quinolizidin. Til sidst adskilles de isomere. Reaktionsskemaerne er anført herunder ("almene reaktionsforløb"), og disse fører udelukkende til forbindelser, i hvilke R betegner -CCKX^Hg eller -CN (i hvert af disse tilfælde dannes 2 isomere, dvs. der fås i alt 4 forbindelser). Alle andre derivater er afledt af disse forbindelser: - enten direkte, dvs. syrerne fås ved forsæbning af esterne (se skemaerne "specielle reaktionfforløb",The process of the invention consists in condensing 2-aminoethyl-3-indole with 1-chloro-4- (A) -4-chlorocarbonyl-hexane, where A represents -COCX or -CN, to form the corresponding amide. Subsequently, the amide is subjected to strong alkaline action, whereby HCl is expelled while a cyclization occurs at the nitrogen atom of the 3-indole substituent. By treating the thus obtained product with dehydrating agent and then with a perchloirate salt, a quinolizidine ring formation is obtained and the resulting quinolizidinium perchlorate is hydrogenated to form a mixture of isomers of the corresponding indolo (2,3-a) quinolizidine. Eventually, the isomers separate. The reaction schemes are listed below ("general reaction") and these only lead to compounds in which R represents -CCKX 3 Hg or -CN (in each of these cases 2 isomers are formed, i.e., a total of 4 compounds are obtained). All other derivatives are derived from these compounds: - either directly, ie. the acids are obtained by saponification of the esters (see the "special reaction procedures" diagrams,

DK 154430 BDK 154430 B

3 hvor Å er -COOCgHjj), og methylenamino-forbindelser-ne fås fra nitrilerne ved reduktion med lithiumalu-miniumhydrid (samme reaktionsskemaer, hvor A er -CN) - eller ud fra syrerne eller methylenamino-forbindel-serne ved velkendte metoder.3 where Å is -COOCgHjj) and the methylenamino compounds are obtained from the nitriles by reduction with lithium aluminum hydride (the same reaction schemes where A is -CN) - or from the acids or methylenamino compounds by well known methods.

I reaktionsskemaeme benyttes følgende betegnelser: (I) angiver cis-isomere, og (II) angiver trans-isomere.In the reaction schemes, the following terms are used: (I) denotes cis isomers and (II) denotes trans isomers.

1(a) til l(i) betegner de forskellige trin ifølge eksempel 1, hvori udgangsmaterialet er 4-ethoxycarbo-nyl-derivatet og slutprodukterne er syrer eller syrederivater.1 (a) to 1 (i) denote the various steps of Example 1 wherein the starting material is the 4-ethoxycarbonyl derivative and the final products are acids or acid derivatives.

2(a) til 2(g) angiver de forskellige trin ifølge eksempel 2, hvori udgangsmaterialet er 4-cyano-derivater og slutprodukterne er methylenamino-forbindelser eller derivater heraf.2 (a) to 2 (g) indicate the various steps of Example 2 wherein the starting material is 4-cyano derivatives and the end products are methylenamino compounds or derivatives thereof.

4 DK 154430 B4 DK 154430 B

Almene reaktionsforløb 1 (a) eller 2 (a) *· yy— T J ♦ C2H5 - C - (CH2)3 Cl >> Lk J π /C1 coci ''jj H Sv'av^ 1 (b) eller 2(b) kallum-tert-butoxidGeneral Reaction Programs 1 (a) or 2 (a) * · yy— TJ ♦ C2H5 - C - (CH2) 3 Cl >> Lk J π / C1 coci 'jj H Sv'av ^ 1 (b) or 2 (b) ) called tert-butoxide

1 (cl V1 (cl V

elleror

I Λ . C104 ® *-3 I II Λ. C104 ® * -3 I I

/Vn t,cl0,vv VS/ Vn t, cl0, vv VS

A ^A ^

k \ Sk \ S

\ Hj/Pt 1 (d) \ 1 (d) 2 W XN. 2 (e)\ Hj / Pt 1 (d) \ 1 (d) 2 W XN. 2 (e)

SnCO OoSSnCO OoS

vss vss V v 5vss vss V v 5

Specielle reaktionsforløb 1 54430 BSpecial reaction steps 1 54430 B

A = -C00C2H5 A AlA = -C00C2H5 A Al

Wi i. W-f o '' o ^Wi i .W-f o '' o ^

1(h) KOH x(e) K0H1 (h) KOH x (e) KOH

/VXA/ VXA

li i* CJOLiili i * CJOLii

Mjf) ΊΠΤ "V< 0 ^ ϋ (I) (Π)Mjf) ΊΠΤ "V <0 ^ ϋ (I) (Π)

A = -CNA = -CN

ΟοΦ (XX&ΦοΦ (XX &

A AA A

wc'' v 2(g) 2(f) \toilet v 2 (g) 2 (f) \

LiAlH4 LiAlH4LiAlH4 LiAlH4

Cell ¢1¾Cell ¢ 1¾

A AA A

H2N-h2n---''H 2 h2n --- ''

DK 154430 BDK 154430 B

66

Forbindelser med formel (I) eller (II), i hvilke R er en substitueret aminomethylgruppe, såvel som E homoazae-burnamoniner, kan fremstilles ud fra de ovenanførte produkter, hvor R er COOH eller CI^NE^ ved i sig selv kendte metoder til indre omdannelse af substituentgrup-per.Compounds of formula (I) or (II), in which R is a substituted aminomethyl group, as well as E homoazae burnamonines, can be prepared from the above products wherein R is COOH or Cl 2 NE 2 by methods known per se to internal conversion of substituent groups.

Fremgangsmåden ifølge opfindelsen illustreres nærmere ved de følgende eksempler.The process of the invention is further illustrated by the following examples.

Eksempel 1 (a) Fremstilling af 3-/21 - (2,,-ethoxycarbonyl-2"-ethyl-5"-chlor-valerovlamino)-ethvl7-indol_Example 1 (a) Preparation of 3- / 21 - (2,2-Ethoxycarbonyl-2 "-ethyl-5" -chloro-valerovlamino) -ethyl-indole

Til en suspension af 2,5 g (0,0184 mol) 3-(2*-amino-ethyl)-indol (tryptamin) i 50 ml tør chloroform indeholdende 2 g (0,02) triethylamin kølet i et isbad blev dråbevis tilsat 4,7 g (0,0184 mol) 2-ethyl-2-ethoxycarbonyl-5-chlor-valeroylchlorid. Efter omrøring i 2 timer ved stuetemperatur blev opløsningen udvasket med fortyndet saltsyre. Den organiske fase blev tørret og inddampet under reduceret tryk til opnåelse af 6,6 g af ovennævnte produkt, som efter omkrystallisation fra petroleumether/isopropylether gav et udbytte på 95%· Smeltepunkt: 76°C. Analyseresultater:To a suspension of 2.5 g (0.0184 mol) of 3- (2 * -aminoethyl) -indole (tryptamine) in 50 ml of dry chloroform containing 2 g (0.02) of triethylamine cooled in an ice bath was added dropwise 4.7 g (0.0184 mol) of 2-ethyl-2-ethoxycarbonyl-5-chloro-valeroyl chloride. After stirring for 2 hours at room temperature, the solution was washed with dilute hydrochloric acid. The organic phase was dried and evaporated under reduced pressure to give 6.6 g of the above product, which after recrystallization from petroleum ether / isopropyl ether gave a yield of 95% Melting point: 76 ° C. Analytical results:

IR (KBr) 3350 og 3300 cnf1 NHIR (KBr) 3350 and 3300 cnf1 NH

1735 cm ^ CO ester 1640 cm-·*· CO amid.1735 cm ^ CO ester 1640 cm- · * · CO amide.

Beregnet for C20H27N203C1 : C= 63,40%, H= 7,18%, N= 7,40% Fundet: C= 63,39%, H= 7,05%, N= 7,51%Calculated for C 20 H 27 N 2 O 3 Cl: C = 63.40%, H = 7.18%, N = 7.40% Found: C = 63.39%, H = 7.05%, N = 7.51%

DK 154430 BDK 154430 B

7 (b) Fremstilling af l-/~(2,-indol-3,,-ylethyl)-3-ethyl- 3-ethoxvcarbonvl7-2-piperidon_____7 (b) Preparation of 1- [(2, -indole-3, - ylethyl) -3-ethyl-3-ethoxycarbonyl] -2-piperidone

Til en suspension af 34,4 g (0,0908 mol) af ovennævnte forbindelse i 150 ml af en 1:1 blanding af benzen og hexamethylphosphortriamid, kølet i et isbad, blev langsomt og i nitrogenatmosfære tilsat 10,6 g (0,0946 mol) kalium-tert-butoxid. Efter omrøring i 8 timer ved stuetemperatur blev opløsningen udhældt i kold fortyndet saltsyre. Den vandige fase blev efter dekantering ekstraheret 2 gange med benzen, hvorefter den resulterende organiske fase blev udvasket 2 gange med vand, tørret og inddampet under reduceret tryk til opnåelse af 30 g af det ønskede produkt. Dette blev omkrystalliseret fra isopropylether til et udbytte på 96%. Smeltepunkt: 29°C. Analyseresultater: IR (KBr) 3250 cm”1 NH indol 1730 cm"1 CO ester 1620 cm”1 CO amidTo a suspension of 34.4 g (0.0908 mol) of the above compound in 150 ml of a 1: 1 mixture of benzene and hexamethylphosphor triamide, cooled in an ice bath, was added slowly and in nitrogen atmosphere 10.6 g (0.0946 mole) potassium tert-butoxide. After stirring for 8 hours at room temperature, the solution was poured into cold dilute hydrochloric acid. After decanting, the aqueous phase was extracted twice with benzene, after which the resulting organic phase was washed twice with water, dried and evaporated under reduced pressure to give 30 g of the desired product. This was recrystallized from isopropyl ether to yield 96%. Melting point: 29 ° C. Analysis results: IR (KBr) 3250 cm ”1 1 NH indole 1730 cm" 1 CO ester 1620 cm ”1 CO amide

Beregnet for C20H26W2°3: C=70,15%, H=7,65%, N=8,13%Calculated for C 20 H 26 W 2 ° C: C = 70.15%, H = 7.65%, N = 8.13%

Fundet: C=69,97%, H=7,65%, N=8,20% (c) Fremstilling af l-ethyl-l-ethoxycarbonyl-5,12b-didehvdro-indolo-(2.3-a)auinolizidiniumnerchlorat 240 ml destilleret phosphonylchlorid blev udhældt i en opløsning af 30 g (0,0876 mol) af ovennævnte forbindelse i 480 ml tør toluen. Denne opløsning blev opvarmet under tilbagesvaling i 9 timer i nærvær af et vandsugende middel. Overskydende phosphorylchlorid og toluen blev derefter fjernet ved inddampning under reduceret tryk. Inddampningsresten blev opsamlet med methylendichlorid, hvorefter opløsningen blev udvasket med vand, tørretFound: C = 69.97%, H = 7.65%, N = 8.20% (c) Preparation of 1-ethyl-1-ethoxycarbonyl-5,12b-didehydro-indolo- (2,3-a) auinolizidinium chloride 240 ml of distilled phosphonyl chloride was poured into a solution of 30 g (0.0876 mol) of the above compound in 480 ml of dry toluene. This solution was refluxed for 9 hours in the presence of a water-soaking agent. Excess phosphoryl chloride and toluene were then removed by evaporation under reduced pressure. The residue was collected with methylene dichloride and the solution was washed with water, dried

DK 154430 BDK 154430 B

8 over natriumsulfat og inddampet under reduceret tryk.8 over sodium sulfate and evaporated under reduced pressure.

En del af opløsningen blev rystet med en 1 M vandig opløsning af lithiumperchlorat, og efter dekantering af den vandige fase, udvaskning med vand, tørring over natriumsulfat og bortdampning af opløsningsmidlet under reduceret tryk opnåedes et gult pulver, der blev omkrystalliseret fra ethanol. Smeltepunkt for det resulterende produkt: 71°C. Analyseresultater:Part of the solution was shaken with a 1 M aqueous solution of lithium perchlorate, and after decanting the aqueous phase, washing out with water, drying over sodium sulfate and evaporation of the solvent under reduced pressure, a yellow powder which was recrystallized from ethanol was obtained. Melting point of the resulting product: 71 ° C. Analytical results:

IR (KBr) 3340 cm"1 NHIR (KBr) 3340 cm -1 NH

1740 cm"1 CO ester 1625 cm"1 C=NC& (d) Fremstilling af 1-ethyl-l-ethoxycarbonyl-indolo (2,3-a)-quinolizidin (I2b-H , l-C^H^ trans- og cis-i s omere)1740 cm "1 CO ester 1625 cm" 1 C = NC & (d) Preparation of 1-ethyl-1-ethoxycarbonyl-indolo (2,3-a) -quinolizidine (I2b-H, 1C i s omere)

En opløsning af 6,25 g (0,0147 mol) af ovennævnte per-chloratsalt i 80 ml ethanol blev hydrogeneret i 12 timer i nærvær af 0,3 g platinoxid. Efter filtrering blev ethanolen bortdampet under reduceret tryk, og remanensen blev opsamlet med methylendichlorid og omrystet med 5% natriumhydroxid. Den organiske fase blev herefter dekanteret fra og udvasket med destilleret vand. En opløsning af produktet blev chromatograferet med methylendichlorid over 100 g siliciumoxid og elu-eret med samme opløsningsmiddel. Herved udskiftes 1,12 g (udbytte 25%) af en første fraktion, som var 12b-H, l-C^H^-trans-isomeren af produktet. Smeltepunkt: 112°C (omkrystalliseret fra petroleumether/isopropylether). Analyseresultater: eA solution of 6.25 g (0.0147 mol) of the above perchlorate salt in 80 ml of ethanol was hydrogenated for 12 hours in the presence of 0.3 g of platinum oxide. After filtration, the ethanol was evaporated under reduced pressure and the residue was collected with methylene dichloride and shaken with 5% sodium hydroxide. The organic phase was then decanted off and washed with distilled water. A solution of the product was chromatographed with methylene dichloride over 100 g of silica and eluted with the same solvent. Hereby, 1.12 g (yield 25%) of a first fraction which was the 12b-H, 1-C ^ H ^ trans isomer of the product is replaced. Melting point: 112 ° C (recrystallized from petroleum ether / isopropyl ether). Analysis results: e

IR (KBr) 3410 cm"1 NHIR (KBr) 3410 cm -1 NH

2770, 2805, 2825 cm"1 Bohlmann-bånd 1710 cm”1 CO ester2770, 2805, 2825 cm "1 Bohlmann band 1710 cm" 1 CO ester

DK 154430 BDK 154430 B

9 NMR (CDClj, 90 MHZ): blandt andre signaler: 8,5 S OH (s) (NH indol) 4.35 & 2H (q) (0-CH2-CH3) 3,85 £ IH (s) (H på C9a) 1.35 C 3H (t) (CH3-CH2-0-) 0,75 £ 3H (t) (CH3-CH2)9 NMR (CDCl 3, 90 MHz): among other signals: 8.5 S OH (s) (NH indole) 4.35 & 2H (q) (O-CH 2 -CH 3) 3.85 M 1.35 C 3H (t) (CH 3 -CH 2 -O-) 0.75 3 H (t) (CH 3 -CH

Beregnet for C20^26N2°2: C=73,59%, H=8,03%, N=8,58%Calcd for C20 N2 O2: C = 73.59%, H = 8.03%, N = 8.58%

Pundet: 0=73,47%, H=8,12%, N=8,33%.Pound: 0 = 73.47%, H = 8.12%, N = 8.33%.

Senere fraktioner fra chromatograferingen gav 1,8 g af en olie, som var 12b-H, 1-C2H3 cis-isomeren af det ønskede produkt.Later fractions from the chromatography afforded 1.8 g of an oil which was the 12b-H, 1-C2H3 cis isomer of the desired product.

Analyseresultater:Analytical results:

IR (KBr) 3420 cm"1 NHIR (KBr) 3420 cm -1 NH

3750, 3800 cm"1 Bohlmann-bånd 1705 cm"1 CO ester NMR (CCl^, 90 MHZ)3750, 3800 cm "1 Bohlmann band 1705 cm" CO CO ester NMR (CCl ^, 90 MHz)

Blandt andre signaler: 7,78 S IH (s) (NH indol) 4,15 S 2H (q) (-0CH2-CH3) 3,93 S IH (s) (H på C9a) 1,09 S 3H (t) (CH3-CH2-0) 0,9 S 3H (t) (CH3-CH2-)Among other signals: 7.78 S 1H (s) (NH indole) 4.15 S 2H (q) (-0CH 2 -CH 3) 3.93 S 1H (s) (H on C9a) 1.09 S 3H (t (CH3-CH2-O) 0.9 S 3H (t) (CH3-CH2-)

Hydrochloridet, omkrystalliseret fra isopropanol, havde smeltepunkt over 260°C.The hydrochloride, recrystallized from isopropanol, had a melting point above 260 ° C.

Beregnet for C20H2gN202.HCl.l,5 H20: C=6l,57%, H=7,75%, N=7,18%Calculated for C20 H20 N2 O2 .HCl.1.5 H2 O: C = 6.1, 57%, H = 7.75%, N = 7.18%

Pundet C=6l,51%, H=7,33%, N=7,35%Pound C = 6.1, 51%, H = 7.33%, N = 7.35%

DK 154430BDK 154430B

10 (e) Fremstilling af 1-ethyl-l-carboxy-indolo (2,3-a) quinolizidin (12b-H, 102^ trans-isomer), hydro-chlorid —Τ^Ί H I HCl . H ! HOOC' \(E) Preparation of 1-ethyl-1-carboxy-indolo (2,3-a) quinolizidine (12b-H, 102 ^ trans-isomer), hydrochloride -ΤΤΤH in HCl. H! HOOC '\

Til en opløsning af 8,8 g af den i trin (d) opnåede ester i 100 ml ethanol blev tilsat 8,8 g Κ0Η, hvorefter blandingen opvarmedes under tilbage svaling i 12 timer. Opløsningsmidlet blev evakueret mider reduceret tryk, hvorpå remanensen blev behandlet med isvand og gjort sur med koncentreret saltsyre. Herved udfældede hydro-chloridet, som blev skilt fra, vasket og tørret. Udbyttet blev 9,5 g (100%) udkrystalliseret med 1 mol krystalvand. Smeltepunkt:> 260°C. Analyseresultater:To a solution of 8.8 g of the ester obtained in step (d) in 100 ml of ethanol was added 8.8 g of Η0Η, after which the mixture was heated under reflux for 12 hours. The solvent was evacuated under reduced pressure, after which the residue was treated with ice water and acidified with concentrated hydrochloric acid. The hydrochloride, which was separated, precipitated, washed and dried. The yield was crystallized 9.5 g (100%) with 1 mole of crystal water. Melting point:> 260 ° C. Analytical results:

Formel Ο-^^ϊ^ί^ίΗΟΙ,^Ο molvægt: 355·Formula Ο - ^^ ϊ ^ ί ^ ίΗΟΙ, ^ Ο Molecular Weight: 355 ·

C Η NC Η N

Beregnet 61,20% 7,08% 7,93%Calculated 61.20% 7.08% 7.93%

Fundet: 61,01% 6,75% 7,72%Found: 61.01% 6.75% 7.72%

IR (KBr) 3340 cm"1 NHIR (KBr) 3340 cm -1 NH

1705 cm’1 (-C-0H) u 01705 cm -1 (-C-OH) u 0

DK 154430 BDK 154430 B

11 (f) Fremstilling af l-ethyl-carboxy-indolo-(2,3-a)-quinolizidin (12b-H. 1-CoHr- cis- isomer) O-(F) Preparation of 1-ethyl-carboxy-indolo- (2,3-a) -quinolizidine (12b-H. 1-CoHr-cis isomer) O-

Vh H0CxvN/^ 8 -·,V H0CxvN / ^ 8 - ·,

Til en opløsning af 6,8 g 1-ethyl-l-ethoxycarboxyl-indolo(2,3-a)quinolizidin (I2b-H, l-C^H^ cis-isomer), opnået i trin (d), i 100 ml 95% ethanol blev tilsat 6,8 g kaliumhydroxid. Blandingen varmedes under tilbagesvaling i 12 timer, opløsningsmidlet bortdampedes under reduceret tryk, og remanensen blev behandlet med isvand og gjort sur med HC1 til pH 4,5· Det udkrystalliserede produkt blev skilt fra, vasket og tørret til opnåelse af 4,1 g syre.To a solution of 6.8 g of 1-ethyl-1-ethoxycarboxyl-indolo (2,3-a) quinolizidine (I2b-H, 1C ^ H ^ cis isomer), obtained in step (d), in 100 ml of 95 % ethanol was added 6.8 g of potassium hydroxide. The mixture was heated under reflux for 12 hours, the solvent evaporated under reduced pressure, and the residue was treated with ice water and acidified with HCl to pH 4.5. The crystallized product was separated, washed and dried to give 4.1 g of acid.

Analyse: ^18^22^2^2 M=298,37Analysis: ^ 18 ^ 22 ^ 2 ^ 2 M = 298.37

C Η NC Η N

Beregnet 72,45% 7,43% 9,37%Calculated 72.45% 7.43% 9.37%

Fundet: 72,61% 7,49% 9,20% IR 1620 cm'1 "V CO, OH tilknyttetFound: 72.61% 7.49% 9.20% IR 1620 cm -1 V CO, OH attached

DK 154430 BDK 154430 B

12 (g) Fremstilling af — D nor eburnamonin iim,u ΠτΤ^12 (g) Preparation of - D nor eburnamonin iim, u ΠτΤ ^

Cn. .JL Jv [ >11 2) NaOH vandi^^/'''^\ViL^^ H J_'Cn. .JL Jv [> 11 2) NaOH vandi ^^ / '' '^ \ ViL ^^ H J_'

moc'i^' Lmoc'i ^ 'L

Til en suspension af 6 g (0,0179 mol) 1-ethyl-l-carboxy-indolo(2,3-a)quinolizidin (I2b-H, 1-02Η^ cis-isomer) fra det foregående trin ( f) i 60 ml tør benzen blev dråbevis sat 30 ml oxalylchlorid. Suspensionen blev omrørt i 2 timer ved stuetemperatur og derefter varmet under tilbagesvaling i 9 timer. Opløsningsmidlerne blev bort-dampet under reduceret tryk og remanensen behandlet med methylenchlorid og omrørt i nærvær af en fortyndet sodaopløsning. Den organiske opløsning blev udvasket med vand, tørret over magnesiumsulfat og inddampet under reduceret tryk til opnåelse af 4,25 g af det søgte produkt (udbytte: 83%)·To a suspension of 6 g (0.0179 mol) of 1-ethyl-1-carboxy-indolo (2,3-a) quinolizidine (I2b-H, 1-02Η cis isomer) from the previous step (f) in 60 ml of dry benzene were added dropwise 30 ml of oxalyl chloride. The suspension was stirred for 2 hours at room temperature and then refluxed for 9 hours. The solvents were evaporated under reduced pressure and the residue treated with methylene chloride and stirred in the presence of a dilute soda solution. The organic solution was washed with water, dried over magnesium sulfate and evaporated under reduced pressure to give 4.25 g of the product sought (yield: 83%) ·

Efter udvaskning på en aluminiumoxidkolonne opnåedes 3,25 g af et beige krystallinsk produkt. Smeltepunkt: 136°C (diisopropyloxid).After washing out on an alumina column, 3.25 g of a beige crystalline product was obtained. Melting point: 136 ° C (diisopropyloxide).

IR (KBr) : 2805, 2845, 1735, 1660 cm-1 C18H20N2° = 280,96.IR (KBr): 2805, 2845, 1735, 1660 cm -1 C18 H20 N2 ° = 280.96.

Beregnet % : C 77,11% H 7,19% N 9,99%Calculated%: C 77.11% H 7.19% N 9.99%

Fundet: 77,54% 7,78% 10,09%Found: 77.54% 7.78% 10.09%

DK 154430 BDK 154430 B

1313

HjNMR (COCl^) reference int. IMS = O 7,9-7,7 (m) aromatisk, 7,5-7,05 (m) 3H aromatisk, 4,3 (m) IH, 1,1 (t) ch3-ch2.HjNMR (COCl4) reference int. IMS = 0 7.9-7.7 (m) aromatic, 7.5-7.05 (m) 3H aromatic, 4.3 (m) 1H, 1.1 (t) ch 3 -ch 2.

Hvdrochloridhydrochloride

Den fornødne mængde 7N saltsyre blev sat til en opløsning af 3,25 g base i 30 ml absolut alkohol. Opløsningsmidlerne blev bortdampet under reduceret tryk ved 30°C, og remanensen gav, efter behandling med acetone, 3,32 g af et hvidt, krystallinsk produkt med smeltepunkt 264°C.The required amount of 7N hydrochloric acid was added to a solution of 3.25 g of base in 30 ml of absolute alcohol. The solvents were evaporated under reduced pressure at 30 ° C and the residue, after treatment with acetone, yielded 3.32 g of a white crystalline product, mp 264 ° C.

IR (KBr) : 3400, 2470, 2320, 1740, 1680 cm”1 C^NMR (D20) reference dioxan S ppm 107,426 C= 0, -13,712 CH, -82,162 CH3IR (KBr): 3400, 2470, 2320, 1740, 1680 cm ”1 C NMR (D₂O) reference dioxane S ppm 107.426 C = O, -13.712 CH, -82.162 CH 3

Eksempel 2 (a) Fremstilling af 3-/2,-(2,,-cyano~2,I-ethyl-5"-chlor-valerovlamino)-ethvl7-indol.Example 2 (a) Preparation of 3- / 2, - (2, - cyano-2,1-ethyl-5 "-chloro-valerovlamino) -ethyl-indole.

I en 1 liters kolbe blev anbragt 31 g (0,194 mol) tryp-tamin, 500 ml dichlormethan og 20 g (0,198 mol) triethyl-amin. Blandingen blev kølet til 0°C over is, og der blev tilsat 40 g (0,192 mol) 2-cyano-2-ethyl-5-chlor-valeroyl-chlorid opløst i 150 ml methyldichlorid. Efter 2 timer ved stuetemperatur blev blandingen vasket med vand og derefter med 10% saltsyre og 10% natriumhydroxid. Derefter blev den tørret, og opløsningsmidlet blev bortdampet. Produktet,omkrystalliseret fra isopropylether/ petroleumether, smeltede ved 120°C (udbytte 40 g) Analyseresultater:Into a 1 liter flask were placed 31 g (0.194 mole) of tryptamine, 500 ml of dichloromethane and 20 g (0.198 mole) of triethylamine. The mixture was cooled to 0 ° C over ice and 40 g (0.192 mol) of 2-cyano-2-ethyl-5-chloro-valeroyl chloride dissolved in 150 ml of methyl dichloride was added. After 2 hours at room temperature, the mixture was washed with water and then with 10% hydrochloric acid and 10% sodium hydroxide. Then it was dried and the solvent evaporated. The product, recrystallized from isopropyl ether / petroleum ether, melted at 120 ° C (yield 40 g).

DK 154430BDK 154430B

14 IR (KBr) 3400 cm-"*· NH indol 3340 cm-·*· NH amid14 IR (KBr) 3400 cm - NH NH indole 3340 cm- NH NH amide

2860 cm-1 CN2860 cm -1 CN

1660 cm"1 C-N1660 cm -1 C-N

88

Beregnet for ci8H22N3C10 : 0=65,0%, H=6,64%, N=12,65%Calcd for c18 H22 N3 Cl2: 0 = 65.0%, H = 6.64%, N = 12.65%

Pundet: 0=64,03%, H=6,78%, N=12,60% (b) Fremstilling af l-/2,-indol-3M-yl-ethyl)-3-ethyl- 3-cvano7-2-piperidon I en 1 liters rundbundet kolbe blev anbragt 22 g (0,0665 mol) af produktet fra trin (a) ovenfor, 200 ml tetrahydrofuran og 300 ml t-butanol. Blandingen blev afkølet til 0°C over is, og der blev langsomt tilsat v 8,5 g (0,076 mol) kalium-tert-butoxid. Efter 2 timer ved stuetemperatur blev blandingen reduceret i volumen og hydrolyseret. Den organiske fase blev extrahe-ret med methylendichlorid, udvasket med vand og tørret, hvorefter opløsningsmidlet blev bortdampet. Det ønskede produkt, omkrystalliseret fra en 1:1 blanding af ethanol og ether, smeltede ved 180°C (udbytte: 15 g, 80%). Analyseresultater: IR 3400 cm"1 NH indolPound: 0 = 64.03%, H = 6.78%, N = 12.60% (b) Preparation of 1- (2-indol-3M-yl-ethyl) -3-ethyl-3-cyano-7 2-Piperidone Into a 1 liter round bottom flask was placed 22 g (0.0665 mol) of the product from step (a) above, 200 ml of tetrahydrofuran and 300 ml of t-butanol. The mixture was cooled to 0 ° C over ice and 8.5 g (0.076 mole) of potassium tert-butoxide was added slowly. After 2 hours at room temperature, the mixture was reduced in volume and hydrolyzed. The organic phase was extracted with methylene dichloride, washed with water and dried, then the solvent was evaporated. The desired product, recrystallized from a 1: 1 mixture of ethanol and ether, melted at 180 ° C (yield: 15 g, 80%). Analysis results: IR 3400 cm -1 NH indole

2260 cm"1 CN2260 cm "1 CN

1635 cm"1 C-N1635 cm -1 C-N

IIII

00

Beregnet for ^18^23^3^ C=73,2%, H=7,l%, N=l4,2%Calcd for ^ 18 ^ 23 ^ 3 ^ C = 73.2%, H = 7.1%, N = 144.2%

Fundet: C=72,46%, H=7,15%, N=l4,01%Found: C = 72.46%, H = 7.15%, N = 4.01%

DK 154430 BDK 154430 B

15 (c) Fremstilling af l-ethyl-l-cyano-5,12b-didehydro- indolo(2,5-a)-auinolizidiniumoerchlorat_ I en 1 liters kolbe blev under omrøring anbragt 50 g (0,169 mol) af produktet fra trin (b) og 700 ml phos-phorylchlorid. Efter 20 timers opvarmning under tilbagesvaling blev reaktionsblandingen opkoncentreret og ex-traheret 2 eller 3 gange med 500 ml methylendichlorid, som derpå fjernedes ved inddampning. Produktet blev opsamlet med 300 ml methylendichlorid og afkølet over is, hvorefter 300 ml af en 1 molær opløsning af lithium-perchlorat blev tilsat under kraftig omrøring. Der dannedes et gult bundfald, som efter omkrystallisation fra methanol smeltede ved 260°C (udbytte 44 g, 70%). Analyseresultater: IR 3400 cm”1 NH indol(C) Preparation of 1-ethyl-1-cyano-5,12b-didehydroindolo (2,5-a) -auinolizidinium orochlorate In a 1 liter flask, 50 g (0.169 mol) of the product of step ( b) and 700 ml of phosphoryl chloride. After 20 hours of refluxing, the reaction mixture was concentrated and extracted 2 or 3 times with 500 ml of methylene dichloride, which was then removed by evaporation. The product was collected with 300 ml of methylene dichloride and cooled over ice, then 300 ml of a 1 molar solution of lithium perchlorate was added with vigorous stirring. A yellow precipitate formed which, after recrystallization from methanol, melted at 260 ° C (yield 44 g, 70%). Analysis results: IR 3400 cm -1 NH indole

2260 cm"1 C=N2260 cm -1 C = N

1620 cm”1 C=N + (d) Fremstilling af l-ethyl-l-cyano-indol(2,3-a)-quino- lizidin (I2b-H. l-CLE- trans-isomer)_ I en 1 liters rundbundet kolbe blev anbragt 200 ml methanol, 100 ml methylendichlorid og 13,5 g (0,036 mol) af perchloratproduktet fra trin (c). Kolben blev afkølet til omkring 5°C, og der blev tilsat 5 g natrium-borhydrat i små mængder. Opløsningen blev derefter omrørt i 2 timer ved stuetemperatur, koncentreret, wasket med vand og extraheret med methylendichlorid. Efter tørring og bortdampning af opløsningsmidlet opnåedes 8 g gule krystaller, som efifcer omkrystallisation fra isopropylether smeltede ved 160°C (udbytte: 80%). Analyseresultater :1620 cm -1 C = N + (d) Preparation of 1-ethyl-1-cyano-indole (2,3-a) -quinolizidine (I2b-H. 1-CLE-trans isomer) In a 1 One liter round bottom flask was charged with 200 ml of methanol, 100 ml of methylene dichloride and 13.5 g (0.036 mol) of the perchlorate product of step (c). The flask was cooled to about 5 ° C and 5 g of sodium borohydrate was added in small amounts. The solution was then stirred for 2 hours at room temperature, concentrated, washed with water and extracted with methylene dichloride. After drying and evaporation of the solvent, 8 g of yellow crystals were obtained, which after crystallization from isopropyl ether melted at 160 ° C (yield: 80%). Analysis results:

DK 154430 BDK 154430 B

16 IR 3420 cm"1 ^ 3440 cm"1 ^ 2760 cm"1 ^ NH og Bohlmann-bånd 2800 cm"1 )16 IR 3420 cm "1 ^ 3440 cm" 1 ^ 2760 cm "1 ^ NH and Bohlmann band 2800 cm" 1)

2250 cm"1 CN2250 cm "1 CN

NMR (dimethylsulfoxid dg, 80 MHZ) 0,86 S 3H (t) (CH3) 3,77 S IH (s) (H på Cga) 9,66 δ IH (s) (NH)NMR (dimethylsulfoxide dg, 80 MHz) 0.86 S 3H (t) (CH 3) 3.77 S 1 H (s) (H on Cga) 9.66 δ 1H (s) (NH)

Beregnet for C=77,7%, H=7,2%, N=15,2% 0=77,55%, H=7,32%, N=15,10% (e) Fremstilling af l-ethyl-l-cyano-indolo(2,3-a) quinolizidin(l2b-H, l-C2Hc cis-isomer) I en 1 liters kolbe blev anbragt 19 g af perchlorat-produktet fra trin (c), 300 ml 95% ethanol og 40 g zinkpulver. Der blev i en ampul tilsat 100 ml koncentreret saltsyre, og under tilsætningen kunne iagttages svag tilbagesvaling. Blandingen blev hensat ved stuetemperatur i 10 timer, hvorefter den blev koncentreret, vasket med vand og extraheret med methylenchlorid. Den blev gjort basisk med natriumhydroxid og filtreret gennem Cel i te® . Efter dekantering, tørring og bortdampning af opløsningsmidlerne opnåedes 6 g af et i ether uopløseligt produkt med smeltepunkt 250°C. Analyseresultater i IR 3410 cm"1 (NH) 2260 cm"1 (CN)Calculated for C = 77.7%, H = 7.2%, N = 15.2% O = 77.55%, H = 7.32%, N = 15.10% (e) Preparation of 1-ethyl -1-cyano-indolo (2,3-a) quinolizidine (l2b-H, l-C2Hc cis isomer) Into a 1 liter flask was placed 19 g of the perchlorate product from step (c), 300 ml of 95% ethanol and 40 g of zinc powder. 100 ml of concentrated hydrochloric acid was added to an ampoule and slight reflux was observed during the addition. The mixture was allowed to stand at room temperature for 10 hours, then concentrated, washed with water and extracted with methylene chloride. It was made basic with sodium hydroxide and filtered through Cel i tea®. After decanting, drying and evaporation of the solvents, 6 g of an ether-insoluble product were obtained, m.p. 250 ° C. Analysis results in IR 3410 cm -1 (NH) 2260 cm -1 (CN)

DK 154430BDK 154430B

1717

Beregnet for C-^Hp-,N^. 1/4HpO: 0=76,5%, H=7,60%, N=l4,85% 0=76,59%, H=7,80%, N=l4,55%Calculated for C C HHp-, N ^. 1 / 4HpO: 0 = 76.5%, H = 7.60%, N = 144.85% 0 = 76.59%, H = 7.80%, N = 144.55%

Etherextrakterne blev koncentreret til opnåelse af 4 g (totalt udbytte 71,5%) af cls-isomeren af det samme produkt som i trin (d) ovenfor. NMR (dimethylsulfoxid d6, 80 MHZ) 1,05 S 3H (t) (CH3) 3,45 S IH (s) (H på C9a) 10,32 S IH (s) (NH) (f) Fremstilling af l-ethyl-l-aminomethyl--indolo(2-,3-a) quinolizidin(l2b-H, l-CpH^ trans-isomer II) I en 1 liters kolbe blev anbragt 4 g lithiumaluminium-hydrid og 400 ml tør ether. Kolben blev afkølet til 0-5°C, og der blev i små portioner tilsat 8,9 g af produktet fra trin (d). Efter henstand i 1 time ved stuetemperatur blev tilsat 60 ml tør tetrahydrofuran, og blandingen varmedes under tilbagesvaling i 2 timer. Efter afkøling blev dråbevis tilsat 40 ml vand og derefter 200 ml methylendichlorid, hvorpå blandingen blev omrørt .i 15 minutter. Filtrering over CelitiP, tørring_og koncentrering af filtratet gav 7,2 g hvide krystaller, som .efter omkrystallisation fra ether smeltede ved 175°C (udbytte: 80%). Analyseresultater: IR 3280, 3190 cm”1 NH£ 3350 cm”1 NH indol CN-båndet ved ca. 2250 cm”1 mangledeThe ether extracts were concentrated to give 4 g (total yield 71.5%) of the c1 isomer of the same product as in step (d) above. NMR (dimethylsulfoxide d6, 80 MHz) 1.05 S 3 H (t) (CH 3) 3.45 S 1 H (s) (H on C 9a) 10.32 S 1 H (s) (NH) (f) Ethyl 1-aminomethyl-indolo (2-, 3-a) quinolizidine (1,2b-H, 1-CpH 4 trans-isomer II) Into a 1 liter flask was placed 4 g of lithium aluminum hydride and 400 ml of dry ether. The flask was cooled to 0-5 ° C and in small portions 8.9 g of the product of step (d) was added. After standing for 1 hour at room temperature, 60 ml of dry tetrahydrofuran was added and the mixture was heated under reflux for 2 hours. After cooling, 40 ml of water and then 200 ml of methylene dichloride were added dropwise, and the mixture was stirred for 15 minutes. Filtration over CelitiP, drying and concentration of the filtrate gave 7.2 g of white crystals which, after recrystallization from ether, melted at 175 ° C (yield: 80%). Analysis results: IR 3280, 3190 cm -1 NH 3333 cm 1 NH indole CN band at approx. 2250 cm ”1 was missing

Beregnet for C-^H^Ny 0=76,4%, H=8,85%, N=l4,8%Calculated for C- HH ^New O = 76.4%, H = 8.85%, N = 144.8%

Fundet: C=75r,85%, H=8,90%, N=15,52%Found: C = 75r, 85%, H = 8.90%, N = 15.52%

DK 154430 BDK 154430 B

18 (g) Fremstilling af l-ethyl-l-aminomethyl-indolo(2,3-a) quinolizidin(12b-H, l-CgH^ cis-isomer i) 3,4 g lithiumaluminiumhydrid, 200 ml ether og 100 ml tetrahydrofuran blev overført til en 500 ml kolbe, og under afkøling over is tilsattes, i små portioner, 6,9 g af den cis-isomere fra trin (e). Efter 15 timers henstand ved stuetemperatur blev produktet isoleret som angivet i trin (f). Omkrystallisation fra 1:1 diethyl-ether/petroleumether gav 5 g af et produkt med smeltepunkt 42°C (udbytte 71%). Analyse:(G) Preparation of 1-ethyl-1-aminomethyl-indolo (2,3-a) quinolizidine (12b-H, 1-CgH 2 -cis isomer i) 3.4 g of lithium aluminum hydride, 200 ml of ether and 100 ml of tetrahydrofuran was transferred to a 500 ml flask and, under cooling over ice, 6.9 g of the cis isomer of step (e) was added in small portions. After standing for 15 hours at room temperature, the product was isolated as indicated in step (f). Recrystallization from 1: 1 diethyl ether / petroleum ether gave 5 g of a product, mp 42 ° C (yield 71%). Analysis:

Beregnet for 0=76,4%, H=8,85%, N=14,8%Calculated for 0 = 76.4%, H = 8.85%, N = 14.8%

Fundet: 0-76,25%, H=8,6l%, N=l4,43%Found: 0-76.25%, H = 8.61%, N = 144.43%

Eksempel 3 l-ethoxycarbonylaminomethyl-l-ethyl-indolo(2,3-a) quinolizidin-hydrochlorid (I2b-H, 1-0^.^ trans-isomer II) —r^j kJk Ajx'K, -«Cl ÅEXAMPLE 3 1-Ethoxycarbonylaminomethyl-1-ethyl-indolo (2,3-a) quinolizidine hydrochloride (I2b-H, 1-O-trans-isomer II) - R

^CH2 L^ CH2 L

c2h5o.co.nh ^c2h5o.co.nh ^

Til en opløsning af 2 g (0,00705 mol) af trans-produktet (II) fra eksempel 2 (f) i 20 ml dimethoxyethan, kølet til 0°C, blev der skiftevis tilsat portioner af 800 mg ethylchloroformiat opløst i 5 ml dimethoxyethan of 750 ml natriumcarbonat opløst i 5 ml vand, for at holde pH basisk.To a solution of 2 g (0.00705 mol) of the trans product (II) of Example 2 (f) in 20 ml of dimethoxyethane, cooled to 0 ° C, portions of 800 mg of ethyl chloroformate dissolved in 5 ml of dimethoxyethane were alternately added. of 750 ml of sodium carbonate dissolved in 5 ml of water to keep the pH basic.

DK 154430 BDK 154430 B

1919

Efter 3 timers henstamd ved omgivelsestemperatur blev produktet extraheret med diehlormethan, og dichlor-methanekstrakten blev vasket med vand, tørret og ind-dampet til tørhed. Produktet omkrystalliseredes fra ethanol.After standing at ambient temperature for 3 hours, the product was extracted with dichloromethane and the dichloromethane extract was washed with water, dried and evaporated to dryness. The product was recrystallized from ethanol.

Vægt: 2 g Udbytte: 80% Smeltepunkt: 140°CWeight: 2 g Yield: 80% Melting point: 140 ° C

IR 3210 cm-1 amid NHIR 3210 cm -1 amide NH

3400 cm"1 indol NH3400 cm -1 NH indole

2760 og 2800 cm"1 Bohlmann-bånd 1690 cm"1 carbamat C = 0.2760 and 2800 cm "1 Bohlmann band 1690 cm" 1 carbamate C = 0.

Mikroanalyse-resultater:Microanalysis results:

Beregnet for C^H^N^: 0=71,0%, H=8,17%, N=ll,8%Calculated for C ^H ^N₂: 0 = 71.0%, H = 8.17%, N = 11.8%

Fundet: 0=70,94%, H=8,l6%, N=ll,54%Found: 0 = 70.94%, H = 8, 16%, N = 11, 54%

Hydrochloridsaltet blev dannet af ovennævnte 2 g produkt ved at tilsætte 4N HC1 i 20 ml ethanol.The hydrochloride salt was formed from the above 2 g of product by adding 4N HCl in 20 ml of ethanol.

Vægt: 2 g Udbytte: 90% Smeltepunkt: 260°C.Weight: 2 g Yield: 90% Melting point: 260 ° C.

Eksempel 4 l-(3* ,4' ,5'--trimethoxybenzoylaminomethyl)-l-ethyl-indolo (2,3-a) quinolizidin-hydrochlorid (I2b-H, 1-Ctrans-isomer II)Example 4 1- (3 *, 4 ', 5' - trimethoxybenzoylaminomethyl) -1-ethylindolo (2,3-a) quinolizidine hydrochloride (I2b-H, 1-Ctrans isomer II)

_r/N_R / N

H ^ .MCIH + .MCI

CH3°\ ^1CH3 ° / 1

\—\ H\ - \ H

CK30—/ \cO-NH-CH/' CH3°CK30- / c0-NH-CH / -CH3 °

DK 154430 BDK 154430 B

20 I en 250 ml trehalset kolbe forsynet med omrører, fugtfanger af CaC^, termometer og skilletragt anbragtes 2,85 g af trans-produktet i eksempel 2(f), 1,1 g triethylamin og 50 ml dichlormethan. Blandingen blev omrørt og afkølet til 0,2°C. Ved denne temperatur blev langsomt tilsat 2,31 g 3,4,5-trimethoxybenzoyl-chlorid i 15 ml dichlormethan. Tilsætningen foregik over en periode på 15-20 minutter, hvorefter reaktionsblandingen blev omrørt i 1 time ved 0°C og derpå i 15 timer ved omgivelsestemperatur. Reaktionsblandingen blev vasket flere gange med vand, med 1096 vandig natriumhydroxid og igen med vand. Derefter blev den tørret over natriumsulfat og koncentreret til en ikke-krystallinsk masse med marengs-struktur, der smeltede omkring 100°C.In a 250 ml three-necked flask equipped with a stirrer, humidifier of CaCl 2, thermometer and separatory funnel were placed 2.85 g of the trans product of Example 2 (f), 1.1 g of triethylamine and 50 ml of dichloromethane. The mixture was stirred and cooled to 0.2 ° C. At this temperature, 2.31 g of 3,4,5-trimethoxybenzoyl chloride was slowly added in 15 ml of dichloromethane. The addition took place over a period of 15-20 minutes, after which the reaction mixture was stirred for 1 hour at 0 ° C and then for 15 hours at ambient temperature. The reaction mixture was washed several times with water, with 1096 aqueous sodium hydroxide and again with water. Then it was dried over sodium sulfate and concentrated to a non-crystalline meringue structure melting about 100 ° C.

TLC; 90/10 8/10TLC; 90/10 8/10

IR 3230 cm”1 NHIR 3230 cm -1 NH

3190 cm”1 NH3190 cm ”1 NH

2750 og 2800 cm"1 Bohlmann-bånd 1640 cm”1 ‘ C= 0 amid dosering af basen med HC10^ : 97%.2750 and 2800 cm "1 Bohlmann band 1640 cm” 1 C = 0 amide dosing of base with HCl ^: 97%.

Til fremstilling af hydrochloridsaltet blev det ovennævnte produkt opløst i en 1:1 blanding af diisopropyl-ether og isopropanol, og der blev tilsat 4N saltsyre.To prepare the hydrochloride salt, the above product was dissolved in a 1: 1 mixture of diisopropyl ether and isopropanol and 4N hydrochloric acid was added.

Saltet udkrystalliserede i varmen og blev frafiltreret, mens det var varmt. Det blev udvasket med ethanol til opnåelse af 4,5 g (88% udbytte) af produktet.The salt crystallized in the heat and was filtered off while warm. It was washed with ethanol to give 4.5 g (88% yield) of the product.

TLC: 90/10 8/10TLC: 90/10 8/10

Smeltepunkt: 210° bundet til pladen dosering af hydrochlorid : 100% (1 funktion).'Melting point: 210 ° bound to the plate hydrochloride dosing: 100% (1 function).

DK 154430 BDK 154430 B

2121

Mikroanalyse gav følgende resultater:Microanalysis yielded the following results:

Beregnet for C^.HCl : 0=65,45%, H=7,00%, N=8,18% 0=64,34%, H=7,17%, N=8,ll% Fundet: C=64,15%, H=7,l6%, N=7,96%.Calculated for C ^HCl: 0 = 65.45%, H = 7.00%, N = 8.18% 0 = 64.34%, H = 7.17%, N = 8.1% Found: C = 64.15%, H = 7, 16%, N = 7.96%.

Eksempel 5Example 5

1-(N’ /diethylamino ethyl7-N-ure idornethyl)-1-ethyl-indolo (2,3-a) quinolizidin (I2h-H, 1-02^ trans-isømer II1- (N '/ diethylamino ethyl7-N-ureidornethyl) -1-ethyl-indolo (2,3-a) quinolizidine (I2h-H, 1-02 ^ trans isomer II

ΓΊγγΤίΓΊγγΤί

vVyNvVyN

Å (C2H5)2N“CH2CH2-NH-CONHCHg Først fremstilledes det korresponderende 1-phenoxy-carbonylaminomethyl-l-ethyl-derivat. 7 g af trans-forbindelsen II i eksempel 2(f) og 100 ml tetrahydrofuran blev anbragt i en trehalset 500 ml kolbe forsynet med en omrører og to skilletragte. Kolben blev kølet til mellem 0°C og 5°C, og ved denne temperatur blev samtidig tilsat 4,25 g phenylchloroformiat i 50 ml tetrahydrofuran og 2,9 g natriumcarbonat i 50 ml vand. Tilsætningerne skete med sådanne hastigheder, at der kunne opretholdes en pH på 6-7. Man lod herefter kolben antage omgivelsestemperatur og fortsatte omrøringen i 3 timer. Reaktionsproduktet blev extraheret med 100 ml dichlormethan, og extraktet blev vasket flere gange med vand, tørret over natriumsulfat og koncentreret ved inddampning. Der opnåedes herved 11 g af en olie.Å (C2H5) 2N “CH2CH2-NH-CONHCHg First, the corresponding 1-phenoxy-carbonylaminomethyl-1-ethyl derivative was prepared. 7 g of the trans compound II of Example 2 (f) and 100 ml of tetrahydrofuran were placed in a three-necked 500 ml flask equipped with a stirrer and two separating funnels. The flask was cooled to between 0 ° C and 5 ° C, and at this temperature, 4.25 g of phenyl chloroformate in 50 ml of tetrahydrofuran and 2.9 g of sodium carbonate in 50 ml of water were simultaneously added. The additions occurred at such rates that a pH of 6-7 could be maintained. The flask was then allowed to reach ambient temperature and stirring was continued for 3 hours. The reaction product was extracted with 100 ml of dichloromethane and the extract was washed several times with water, dried over sodium sulfate and concentrated by evaporation. 11 g of an oil was thus obtained.

DK 154430 BDK 154430 B

2222

IH 3270 cm-1 NHIH 3270 cm -1 NH

1710 cm"1 C= O1710 cm -1 C = 0

1-ureidomethylforbindelsen blev fremstillet på følgende måde: I en 500 ml kolbe forsynet med køling blev anbragt 11 g af ovennævnte olie, 3,5 g dimethylaminoethylamin og 180 ml methanol. Mængden af benyttet dimethylaminoethylamin svarede til 20% overskud. Blandingen opvarmedes under tilbagesvaling i 2,5 timer, hvorefter metha-nolen bortdampedes. Resten blev opsamlet i dichlor-methan og vasket med 10% vandig NaOH og derefter med vand. Efter tørring over natriumsulfat blev stoffet koncentreret til opnåelse af et gult krystallinsk produkt? dette blev i to trin opsamlet i diethylether og centrifugeret. Første trin gav 4,6 g af et krystallinsk produkt med smeltepunkt 202°C, og andet trin gav 0,8 g krystallinsk produkt med smeltepunkt 198°C. De samlede produkter blev derefter omkrystalliseret fra benzen til opnåelse af 4,65 g slutprodukt.The 1-ureidomethyl compound was prepared as follows: Into a 500 ml flask with cooling was placed 11 g of the above oil, 3.5 g of dimethylaminoethylamine and 180 ml of methanol. The amount of dimethylaminoethylamine used was 20% excess. The mixture was heated at reflux for 2.5 hours, then the methanol was evaporated. The residue was collected in dichloromethane and washed with 10% aqueous NaOH and then with water. After drying over sodium sulfate, the substance was concentrated to give a yellow crystalline product? this was collected in diethyl ether in two steps and centrifuged. The first step yielded 4.6 g of a crystalline product of m.p. 202 ° C, and the second step yielded 0.8 g of crystalline product, mp 198 ° C. The combined products were then recrystallized from benzene to give 4.65 g of final product.

Smeltepunkt: 204°C Udbytte: 45% på basis af amin (II).Melting point: 204 ° C Yield: 45% based on amine (II).

TLC: 90/10 5/10TLC: 90/10 5/10

Dosering af base med HC10^ : 10% (2 funktioner)Dosage of base with HClO ^: 10% (2 functions)

IR 3360 cm"1 NHIR 3360 cm -1 NH

3250 cm"1 NH3250 cm -1 NH

1620 cm"1 C= 0 urinstof1620 cm -1 C = 0 urea

Mikroanalyse gav følgende resultater:Microanalysis yielded the following results:

Beregnet for C2^H^N^0: 0=70,6%, H=9,17%, N=l6,45%Calculated for C₂ ^H ^N ^O: 0 = 70.6%, H = 9.17%, N = 16.45%

Fundet: 0=70,58%, H=9,20:, N=l6,67%.Found: 0 = 70.58%, H = 9.20:, N = 16.67%.

DK 154430 BDK 154430 B

2323

Eksempøl 6 ' 1-pentanoylaminomethyl-l-ethyl-indolo (2,3-a) quinoli-zidin (I2b-H, 1-02¾^ trans-isomer II) fTlExample pool 6 '1-pentanoylaminomethyl-1-ethyl-indolo (2,3-a) quinolizidine (I2b-H, 1-02¾ trans-isomer II) fTl

1 I1 I

/K/ CH3- (CH2) 3-CO-NH-CH^"/ K / CH 3 - (CH 2) 3-CO-NH-CH

Under anvendelse af Hamme reaktionsbetingelser som i eksempel 4 omsattes en opløsning af 5,7 g af transforbindelsen i eksempel 2(f) og 2,1 g triethylamin i 120 ml dichlormethan med en opløsning af 2,45 g penta-noylchlorid i 20 ml dichlormethan. Herved opnåedes 7,8 g af en olie indeholdende en lille rest triethylamin.Using Hamme reaction conditions as in Example 4, a solution of 5.7 g of the trans compound of Example 2 (f) and 2.1 g of triethylamine in 120 ml of dichloromethane was reacted with a solution of 2.45 g of pentanoyl chloride in 20 ml of dichloromethane. . There was thus obtained 7.8 g of an oil containing a small residue of triethylamine.

Ud fra olien var det muligt at opnå krystaller af stoffet med smeltepunkt 110°C.From the oil it was possible to obtain crystals of the substance of melting point 110 ° C.

Eksempel 7 1-ethoxycarbonylaminomethyl-l-ethyl-indolo (2,3-a)-quinolizidin-hydrochlorid (I2b-H, l-C^^ cis-isomer I)Example 7 1-Ethoxycarbonylaminomethyl-1-ethyl-indolo (2,3-a) -quinolizidine hydrochloride (I2b-H, 1-C

I HI H

i '1 j jj .2 HC1 viTT| C2H50-C0-NH-CH2i '1 j jj .2 HC1 viTT | C2H50-C 0-NH-CH 2

DK 154430 BDK 154430 B

2424

Proceduren i eksempel 3 blev gentaget med den ændring, at cis-produktet (I) i eksempel 2(g) blev brugt i stedet for trans-produktet (II) i eksempel 2(f). Der opnåedes 2,1 g af den frie base (84% udbytte). Smeltepunkt: 210°C.The procedure of Example 3 was repeated with the change that the cis product (I) of Example 2 (g) was used instead of the trans product (II) of Example 2 (f). 2.1 g of the free base was obtained (84% yield). Melting point: 210 ° C.

IR 3400 cm-1 indol NHIR 3400 cm -1 indole NH

3210 cm-^ amid NH3210 cm -1 amide NH

2790 og 2810 cm“^ Bohlmann-bånd 1690 cm”·*· carbamat C=02790 and 2810 cm “^ Bohlmann band 1690 cm” · * · carbamate C = 0

Mikroanalyse gav følgende resultater:Microanalysis yielded the following results:

Beregnet for ^21^29^3^21 0=71,0%, H=8,17%, N=ll,82%Calcd for ^ 21 ^ 29 ^ 3 ^ 21 0 = 71.0%, H = 8.17%, N = ll, 82%

Fundet: 0=70,85%, H=8,22%, N=ll,94%.Found: 0 = 70.85%, H = 8.22%, N = 111, 94%.

NMR (CDCl^, intern TMS) 1,1 i(6H, t, CH^ ethyl- og ethylester) 1,5 til 3,5 (15H, bredt bånd) 3.9 ε (2H, q, CH20) 5,65 £ (IH, m, NH-amid) 7,25 S(4H, bredt bånd, aromatisk) 7.9 S (IH, s, NH-indol)NMR (CDCl 3, internal TMS) 1.1 in (6H, t, CH 2 ethyl and ethyl ester) 1.5 to 3.5 (15H, broad band) 3.9 ε (2H, q, CH 2 O) 5.65 (1H, m, NH-amide) 7.25 S (4H, broad band, aromatic) 7.9 S (1H, s, NH-indole)

Hydrochloridsaltet blev fremstillet ved brug af 4N saltsyre i acetone.The hydrochloride salt was prepared using 4N hydrochloric acid in acetone.

Toxicitettoxicity

Man har bestemt LD 50 pr. os hos mus. Forbindelserne fremstillet ifølge opfindelsen udviser en toxicitet, der kan sammenlignes med toxiciteten af vincamin, eller som er mindre end denne. De mest toxiske forbindelser fremstillet ifølge opfindelsen er de, der er omtalt i eksemplerne 2(f) og 3 (LD 50:400 mg"kg, vincamin 450Determined LD 50 per us in mice. The compounds of the invention exhibit a toxicity comparable to or less than the toxicity of vincamine. The most toxic compounds of the invention are those mentioned in Examples 2 (f) and 3 (LD 50: 400 mg "kg, vincamine 450

DK 154430 BDK 154430 B

25 mg/kg). Den mindst toxiske forbindelse er den, der er omtalt i eksempel 4. De øvrige forbindelser udviser en toxicitet, der ligger imellem toxiciteterne for disse to grupper.25 mg / kg). The least toxic compound is that referred to in Example 4. The other compounds exhibit a toxicity which lies between the toxicities of these two groups.

Farmakologipharmacology

Den nyttige virkning af de ifølge opfindelsen fremstillede forbindelser er blevet påvist ved sammenligning af et repræsentativt udvalg af forbindelser, der er fremstillede ifølge opfindelsen, med forbindelsen vincamin, der kendes fra FR patentskrift nr. 2 285 877, og med forbindelserne A og B med formlerneThe useful effect of the compounds of the invention has been demonstrated by comparing a representative range of compounds prepared according to the invention with the compound vincamine known from FR patent no. 2 285 877 and with compounds A and B of the formulas

OyQs cuaOyQs cua

H og h XJH and h XJ

NCCH2CH2 k H2NCH2CH2CH2 kTNCCH2CH2 k H2NCH2CH2CH2 kT

(A) (B) der kendes fra FR patentskrift nr. 2 292 475. De farmakologiske forsøg blev gennemført som beskrevet i det førstnævnte FR patentskrift ved anvendelsen af bedøvede hunde, som blev behandlet med 3,5 mg/kg vincamin eller en hermed ækvivalent mængde af en af de andre forbindelser. Man målte de procentvise ændringer i den femorale og verte-brale blodgennemstrømning, blodtrykket og hjertefrekvensen. Resultaterne fremgår af den følgende tabel, hvoraf det tydeligt ses, at forbindelserne fremstillet ifølge opfindelsen har bemærkelsesværdige egenskaber i forhold til de nært beslægtede referenceforbindelser A, B og vincamin.(A) (B) known from FR Patent No. 2,292,475. The pharmacological tests were carried out as described in the former FR patent using anesthetized dogs treated with 3.5 mg / kg of vincamine or an equivalent thereof. amount of one of the other compounds. Percentage changes in femoral and vertebral blood flow, blood pressure and heart rate were measured. The results are shown in the following table, from which it is clearly seen that the compounds of the invention have remarkable properties in relation to the closely related reference compounds A, B and vincamine.

DK 154430 BDK 154430 B

2626

Femoral Vertebral 1 blodgen- blodgen-Femoral Vertebral 1 blood gene

Forblndelse nemstrøm- nemstrøm- Blodtryk Hjerte-ning ning tryk frekvensBlind light flow flow Blood pressure Heart rate pressure frequency

Vincamin - 13,5 SS - 26,6 % - 29,2 K - 23,8 ϋ A + 54,1 » + 56,1 % - 42 % + 41,8 S! B +301,5 % + 1 % - 22,6 % + 16,3 % Γ c____________________________________ ______________________ ϋ Eks. 3 +67 % +212,8 % ' - 1,6 S + 6,2 (U___________________________________________________________Vincamin - 13.5 SS - 26.6% - 29.2 K - 23.8 ϋ A + 54.1 »+ 56.1% - 42% + 41.8 S! B +301.5% + 1% - 22.6% + 16.3% Γ c____________________________________ ______________________ ϋ Ex. 3 +67% +212.8% - 1.6S + 6.2 (U___________________________________________________________

Eks. 4 + 71,7 % +194,8 % + 1 % +8,4 % r-H U— £ g- Eks. 5 +84,7 % +204 % + 4,8 ,¾ + 9,7 /¾ 4-1 ---------------------------------------------------------- i di Eks. 6 + 57,8 % +185,5 % + 3,4 % + 10,1 % ---------------------------------------------------------- u.in Eks. 7 + 80,1 +173,3 % + 3,6 + 8,3 %Ex. 4 + 71.7% +194.8% + 1% +8.4% r-H U— £ g- Ex. 5 + 84.7% +204% + 4.8, ¾ + 9.7 / ¾ 4-1 -------------------------- -------------------------------- i di Ex. 6 + 57.8% +185.5% + 3.4% + 10.1% ----------------------------- ----------------------------- u.in Ex. 7 + 80.1 + 173.3% + 3.6 + 8.3%

Claims (1)

DK 154430 B Patent-krav: Analogifremgangsmåde til fremstilling af indolo(2,3-a) quinolizidiner med de almene formler (I) og (II): CcQ /iV/ / \ s' R j R" d) " (Π) hvori R betegner -COC^Hj-, -COOH, -CN , en aminomethylgruppe eller en substitueret aminomethylgruppe med formlen R'-Nil-el^-/ hvor R' betegner alkyl, alkanoyl eller alkoxy-carbonyl med op til 5 C-atomer, phenyloxycarbonyl, di-ethylaminoethylaminocarbonyl, trimethyloxybenzoyl eller quanidinocarbonyl, eller hvori R sammen med indolringens nitrogenatom betegner en af grupperne ^N-CO-NH-CI^ og ^N-CO-, eller farmaceutisk acceptable syreadditionssalte deraf, kendetegnet ved, at man kondenserer 2-aminoethyl-3-indol med l-chlor-4-(A)-4-chlorcarfoonyl-hexan, hvor A betegner -COCK^H,. eller -CN, ringslutter det opnåede amid ved indolnitrogenatomet ved behandling med en stærk base, ringslutter den herved opnåede forbindelse ved behandling med et dehydratiserende middel og derefter med et perchloratsalt, hydrogenerer det resulterende quinolizidiniumperchlorat til opnåelse af en blanding af isomere af den tilsvarende indolo-(2,3-a)quinolizidin og adskiller de isomere, hvorefter man om DK 154430 B ønsket underkaster en opnået forbindelse med formel (I) eller (II), hvori R er COCK^H^, en forsæbning til opnåelse af en tilsvarende forbindelse, hvori R er -COOH, og om ønsket omdanner en således opnået forbindelse, hvori R er -COOH, til en forbindelse, hvori R sammen med indolringens nitrogenatom betegner -CO-NH-C^-eller ^N-CO-, eller om ønsket underkaster en opnået forbindelse med formel (I) eller (II), hvori R er -CN, en reduktion til opnåelse af en tilsvarende forbindelse, hvori R er -CH2-NH2, efterfulgt af en kondensation af denne aminomethylenforbindelse med en passende halogeneret gruppe til opnåelse af en forbindelse, hvori R er R'-NH-CH2-,hvor R' har den ovenfor angivne betydning, hvorpå man eventuelt overfører en opnået forbindelse med formel (I) eller (II) i et tilsvarende syreadditionssalt.Patent Claims: Analogous Process for Preparation of Indolo (2,3-a) Quinolizidines of General Formulas (I) and (II): CcQ / iV / / \ s' R j R "d)" (Π) wherein R represents -COC 3 H-, -COOH, -CN, an aminomethyl group or a substituted aminomethyl group of the formula R'-Nil-el 2 - / wherein R 'represents alkyl, alkanoyl or alkoxy-carbonyl having up to 5 C , phenyloxycarbonyl, diethylaminoethylaminocarbonyl, trimethyloxybenzoyl or quanidinocarbonyl, or wherein R together with the nitrogen atom of the indole ring represents one of the groups ^ N-CO-NH-Cl 2 and ^ N-CO-, or pharmaceutically acceptable acid addition salts thereof, characterized by condensation 2-aminoethyl-3-indole with 1-chloro-4- (A) -4-chlorocarphonyl-hexane, where A represents -COCK 3 H,. or -CN, the amide obtained rings at the indole nitrogen atom by treatment with a strong base, cycles the compound obtained by treatment with a dehydrating agent and then with a perchlorate salt, hydrogenates the resulting quinolizidinium perchlorate to give a mixture of isomers of the corresponding indole (2,3-a) quinolizidine and separating the isomers, whereupon, if desired, DK 154430 B is desired to subject an obtained compound of formula (I) or (II) wherein R is COCK wherein R is -COOH and, if desired, converts a compound so obtained, wherein R is -COOH, to a compound wherein R together with the nitrogen atom of the indole ring represents -CO-NH-C desirably, a obtained compound of formula (I) or (II) wherein R is -CN undergoes a reduction to obtain a corresponding compound wherein R is -CH 2 -NH 2 followed by condensation of this aminomethylene compound with a suitable the halogenated group to give a compound wherein R is R'-NH-CH 2 -, where R 'is as defined above, and optionally transfer a obtained compound of formula (I) or (II) into a corresponding acid addition salt.
DK524978A 1977-11-25 1978-11-24 METHOD OF ANALOGUE FOR THE PREPARATION OF INDOLO (2,3-A) QUINOLIZIDIN OR ACID ADDITION SALTS DK154430C (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB4920177 1977-11-25
GB4920177 1977-11-25

Publications (3)

Publication Number Publication Date
DK524978A DK524978A (en) 1979-05-26
DK154430B true DK154430B (en) 1988-11-14
DK154430C DK154430C (en) 1989-04-17

Family

ID=10451538

Family Applications (1)

Application Number Title Priority Date Filing Date
DK524978A DK154430C (en) 1977-11-25 1978-11-24 METHOD OF ANALOGUE FOR THE PREPARATION OF INDOLO (2,3-A) QUINOLIZIDIN OR ACID ADDITION SALTS

Country Status (28)

Country Link
JP (1) JPS6147838B2 (en)
AR (1) AR218514A1 (en)
AT (1) AT372384B (en)
AU (1) AU529108B2 (en)
BE (1) BE872134A (en)
CA (1) CA1100959A (en)
CH (1) CH641181A5 (en)
DE (1) DE2851028A1 (en)
DK (1) DK154430C (en)
EG (1) EG13683A (en)
ES (1) ES475328A1 (en)
FI (1) FI64372C (en)
FR (2) FR2409755A1 (en)
HK (1) HK60884A (en)
IE (1) IE47518B1 (en)
IN (1) IN151146B (en)
IT (1) IT1160263B (en)
LU (1) LU80576A1 (en)
MX (1) MX5529E (en)
MY (1) MY8500029A (en)
NL (1) NL7811562A (en)
NO (1) NO151288C (en)
NZ (1) NZ188974A (en)
PT (1) PT68825A (en)
SE (2) SE431650B (en)
SG (1) SG61182G (en)
WO (1) WO1979000319A1 (en)
ZA (1) ZA786426B (en)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3175900D1 (en) * 1981-11-18 1987-03-12 Thal Claude Indoloquinolizine derivatives, process for their preparation and their therapeutic use
FR2529552B1 (en) * 1982-07-05 1985-09-27 Centre Nat Rech Scient NOVEL PROCESS FOR THE PREPARATION OF VINDOLINE SYNTHESIS INTERMEDIATES AND SYNTHESIS INTERMEDIATES
HU191454B (en) * 1984-10-05 1987-02-27 Richter Gedeon Vegyeszeti Gyar Rt.,Hu Process for producing amides of oktahydro-indolo/2,3-a/quinolyzin-1-yl-alkanecarboxylic acids and pharmaceutically acceptable acid additional salts thereof
HU194220B (en) * 1985-04-19 1988-01-28 Richter Gedeon Vegyeszet Process for production of derivatives of 1,12 b disubstituated-octahydro-indolo /2,3-a/ quinolisine and medical compounds containing thereof
HU195214B (en) * 1985-04-19 1988-04-28 Richter Gedeon Vegyeszet Process for producing 12b-substituted-1-(hydroxymethyl)-octahydro-indolo /2,3-a/ quinolizine derivatives and pharmaceutical preparations comprising these compounds
FI95572C (en) 1987-06-22 1996-02-26 Eisai Co Ltd Process for the preparation of a medicament useful as a piperidine derivative or its pharmaceutical salt
KR100324040B1 (en) * 1993-06-18 2002-07-22 후지사와 야꾸힝 고교 가부시키가이샤 Process for preparing novel intermediates and aminopiperazine derivatives for use in synthetic applications
FR2713644B1 (en) * 1993-12-14 1996-02-09 Adir New analogs of eburnane, process for their preparation and pharmaceutical compositions containing them.
FR2713643B1 (en) * 1993-12-14 1996-06-07 Adir New analogs of eburnane, process for their preparation and pharmaceutical compositions containing them.
DK1532391T4 (en) 2002-06-24 2019-06-24 Saint Gobain Isover INSULATION PLATE FOR DISTRIBUTION CHANNEL
FR2911142A1 (en) * 2007-01-05 2008-07-11 Servier Lab New amino-pyrroloindole and amino-pyridazinoindole derivatives, are tyrosine hydroxylase inducers, useful e.g. for treating anxiety, depression or memory loss
FR2911143A1 (en) * 2007-01-05 2008-07-11 Servier Lab Use of neuroprotective compounds to prepare medicaments for treating neurodegenerative diseases
FR2911141B1 (en) * 2007-01-05 2009-02-20 Servier Lab NOVEL TRIAZABENZO [A] NAPHTHO [2,1,8-CDE] AZULENE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU167366B (en) * 1972-09-06 1975-09-27
BE802387A (en) * 1973-07-16 1973-11-16 Omnium Chimique Sa PROCESS FOR PREPARING VINCAMONE AND EPI-21 VINCAMONE FROM TABERSONIN AND NEW INDOLIC DERIVATIVES.
HU169916B (en) * 1974-09-27 1977-02-28
HU171165B (en) * 1974-11-26 1977-11-28 Richter Gedeon Vegyeszet Process for producing oktahydro-indolo-bracket-2,3-a-bracket closed-quinolizine derivatives
FR2315277A1 (en) * 1975-06-25 1977-01-21 Anvar NEW PENTACYCLIC DERIVATIVES, THEIR PREPARATION AND THE COMPOSITIONS CONTAINING THEM

Also Published As

Publication number Publication date
MX5529E (en) 1983-09-23
SG61182G (en) 1985-02-15
FR2423492A1 (en) 1979-11-16
IT7830171A0 (en) 1978-11-24
PT68825A (en) 1978-12-01
IN151146B (en) 1983-02-26
IT1160263B (en) 1987-03-11
NO151288B (en) 1984-12-03
FR2409755A1 (en) 1979-06-22
FI64372B (en) 1983-07-29
EG13683A (en) 1982-09-30
ATA837478A (en) 1983-02-15
IE782328L (en) 1979-05-25
NZ188974A (en) 1989-10-27
NL7811562A (en) 1979-05-29
SE435622B (en) 1984-10-08
DE2851028C2 (en) 1990-05-03
HK60884A (en) 1984-08-10
FI783581A (en) 1979-05-26
AU4187478A (en) 1979-05-31
DK154430C (en) 1989-04-17
WO1979000319A1 (en) 1979-06-14
FI64372C (en) 1983-11-10
ZA786426B (en) 1979-10-31
NO151288C (en) 1985-03-13
ES475328A1 (en) 1979-04-01
DE2851028A1 (en) 1979-05-31
SE8007845L (en) 1980-11-07
BE872134A (en) 1979-03-16
AT372384B (en) 1983-09-26
IE47518B1 (en) 1984-04-04
LU80576A1 (en) 1979-03-22
FR2423492B1 (en) 1980-12-05
AU529108B2 (en) 1983-05-26
SE431650B (en) 1984-02-20
JPS54500053A (en) 1979-11-08
AR218514A1 (en) 1980-06-13
CH641181A5 (en) 1984-02-15
FR2409755B1 (en) 1980-08-01
DK524978A (en) 1979-05-26
JPS6147838B2 (en) 1986-10-21
CA1100959A (en) 1981-05-12
MY8500029A (en) 1985-12-31
SE7906287L (en) 1979-07-23
NO783958L (en) 1979-05-28

Similar Documents

Publication Publication Date Title
US5604223A (en) N acyl 2 3 benzodiazepine derivatives pharmaceutical compositions containing them and process for preparing same
DK154430B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF INDOLO (2,3-A) QUINOLIZIDIN OR ACID ADDITION SALTS
HU225504B1 (en) Novel halophenyl-(2-(2-thienyl)-ethylamino)-acetonitriles and process for producing them
DK150157B (en) METHOD OF ANALOGUE FOR THE PREPARATION OF FURO, THIENO OR PYRROLO (2,3-D) AZEPINES OR PHYSIOLOGICALLY ACCEPTABLE SALTS THEREOF WITH ACIDS OR BASES
HU182884B (en) Process for preparing 4-phenyl-1,3-benzodiazepine derivatives and pharmaceutically acceptable salts and optical antipodes thereof further pharmaceutical compositions containing these compounds as active substances
PL90072B1 (en) Method for synthesis of optically active lactones[us3876656a]
SU1563594A3 (en) Method of producing alkylenediamine derivatives
JP3563643B2 (en) Imidazoline compounds, intermediates thereof, and methods for producing them, and methods for producing azepine compounds and salts thereof
US4353911A (en) Indolo(2,3-a)quinolizidines, useful in increasing femoral and vertebral blood flow
NO178373B (en) Process for the preparation of therapeutically active ergoline derivatives
US5602131A (en) EburnanE analogues
US3666752A (en) 4,4-diphenylhexahydroazepine compounds
JPH0231075B2 (en)
US3833608A (en) Indole-3-methanesulfonamides
FI88292C (en) FRAME STARTING FOR N- (SULPHONYLMETHYL) FORMAMIDER
US4062891A (en) N-formyl-2,3,5,6-dibenzobicyclo[5.1.0]octan-4-methylamine
US3758500A (en) N-sulfonyl-indole-3-acetamides
JP2021526531A (en) How to make Refite Glast
DK156391B (en) ANALOGY PROCEDURE FOR PREPARING 3-AMINOPYR ROLLER DERIVATIVES
GB2055372A (en) Texahydro-trans-pyridoindole neuroleptic agents
US5162534A (en) Process for the preparation of thiazoline derivatives
FI73197B (en) FOERFARANDE FOER FRAMSTAELLNING AV ETT NYTT, VAENSTERVRIDANDE, TERAPEUTISKT VERKANDE BASISKT DERIVAT AV 9,10-ETANOANTRACEN.
KR820000497B1 (en) Process for preparing new indolo (2,3-a) quinolizidines
HU198023B (en) Process for production of new derivatives of benzamid and medical preparatives containing these compounds as active substance
SU353412A1 (en) METHOD FOR PRODUCING DERIVATIVES OF 1,1L-TRICHLORETHANE

Legal Events

Date Code Title Description
PBP Patent lapsed